| abstract |
There is disclosed compositions and methods relating to or derived from anti-PD-Li nantibodies. More specifically, there is disclosed fully human antibodies that bind PD-Li, nPD-Li-binding fragments and derivatives of such antibodies, and PD-Li -binding n5 polypeptides comprising such fragments. Further still, there is disclosed nucleic acids nencoding such antibodies, antibody fragments and derivatives and polypeptides, cells ncomprising such polynucleotides, methods of making such antibodies, antibody fragments nand derivatives and polypeptides, and methods of using such antibodies, antibody fragments nand derivatives and polypeptides, including methods of treating or diagnosing subjects n10 having PD-Li related disorders or conditions, including various inflammatory disorders and nvarious cancers. |